SG11201811442UA - Formulation of a peptide vaccine - Google Patents
Formulation of a peptide vaccineInfo
- Publication number
- SG11201811442UA SG11201811442UA SG11201811442UA SG11201811442UA SG11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA SG 11201811442U A SG11201811442U A SG 11201811442UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical composition
- pct
- composition
- reconstitution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 2
- 229940023041 peptide vaccine Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16175215 | 2016-06-20 | ||
PCT/EP2017/064882 WO2017220463A1 (en) | 2016-06-20 | 2017-06-19 | Formulation of a peptide vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201811442UA true SG11201811442UA (en) | 2019-01-30 |
Family
ID=56148213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201811442UA SG11201811442UA (en) | 2016-06-20 | 2017-06-19 | Formulation of a peptide vaccine |
Country Status (14)
Country | Link |
---|---|
US (3) | US10702598B2 (de) |
EP (2) | EP3471758A1 (de) |
JP (3) | JP7115803B2 (de) |
KR (2) | KR20230030032A (de) |
CN (2) | CN109641039B (de) |
AU (2) | AU2017281389B2 (de) |
CA (1) | CA3027459A1 (de) |
EA (1) | EA201990071A1 (de) |
IL (2) | IL291537B2 (de) |
MX (2) | MX2018015749A (de) |
MY (1) | MY189551A (de) |
SG (1) | SG11201811442UA (de) |
WO (1) | WO2017220463A1 (de) |
ZA (2) | ZA201900367B (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2767294T3 (es) | 2014-06-26 | 2020-06-17 | Univ Rockefeller | Lisinas de Acinetobacter |
US20180072990A1 (en) * | 2015-03-20 | 2018-03-15 | Children's National Medical Center | Generating virus or other antigen-specific t cells from a naïve t cell population |
SG11201811442UA (en) * | 2016-06-20 | 2019-01-30 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
PE20191842A1 (es) | 2017-05-08 | 2019-12-31 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus |
AU2019213286A1 (en) * | 2018-01-24 | 2020-07-30 | The Council Of The Queensland Institute Of Medical Research | HPV immunotherapy |
KR20210013105A (ko) * | 2018-05-23 | 2021-02-03 | 그릿스톤 온콜로지, 인코포레이티드 | 공유 항원 |
CA3140019A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Bio, Inc. | Modified adenoviruses |
WO2021028929A1 (en) * | 2019-08-15 | 2021-02-18 | National Institute For Biotechnology In The Negev Ltd. | Delivery peptides and methods of using the same |
WO2021247534A2 (en) * | 2020-06-01 | 2021-12-09 | The Broad Institute, Inc. | Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes |
AU2021320896A1 (en) | 2020-08-06 | 2023-03-23 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
EP4370903A1 (de) | 2021-07-12 | 2024-05-22 | ISA Pharmaceuticals B.V. | Verbesserte substanzquantifizierung in komplexen mischungen |
CN113842455B (zh) * | 2021-08-27 | 2022-05-13 | 北京康乐卫士生物技术股份有限公司 | 一种新型冠状病毒疫苗的佐剂及其应用和新型冠状病毒二价重组疫苗 |
KR102545000B1 (ko) * | 2021-10-20 | 2023-06-16 | 전옥님 | 그래핀을 이용한 전자파 차폐 시트 |
WO2023143445A1 (zh) * | 2022-01-25 | 2023-08-03 | 厦门大学 | 用于治疗hbv感染及相关疾病的表位肽及抗体 |
WO2024068636A1 (en) | 2022-09-27 | 2024-04-04 | Isa Pharmaceuticals B.V. | Adjuvanted immunogenic peptides for intradermal administration |
WO2024149888A1 (en) | 2023-01-12 | 2024-07-18 | Isa Pharmaceuticals B.V. | Improved lipopeptide quantification |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2262132T3 (es) | 1991-08-26 | 2006-11-16 | The Scripps Research Institute | Peptidos para la induccion de respuestas de los linfocitos t citoxicos al virus de la hepatitis b. |
US20110097352A9 (en) | 1992-01-29 | 2011-04-28 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
US7611713B2 (en) | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
AU702367B2 (en) | 1993-08-02 | 1999-02-18 | Scripps Research Institute, The | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
CN1762492A (zh) | 1998-05-23 | 2006-04-26 | 莱顿大学医学中心 | Cd40结合分子和ctl肽在用于治疗肿瘤的药物组合物中的用途 |
US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
DE10059631A1 (de) | 2000-12-01 | 2002-07-18 | Medigene Ag | T-Zellepitope des Papillomavirus L1-und E7-Proteins und ihre Verwendung in Diagnostik und Therapie |
EP2112157B1 (de) * | 2000-12-08 | 2014-07-23 | Academisch Ziekenhuis Leiden | Lange Peptide aus 22-45 Aminosäureresten, die die antigenspezifischen Immunreaktionen induzieren und/oder verbessern |
NZ526326A (en) | 2000-12-08 | 2006-09-29 | Academisch Ziekenhuis Leiden | A CTL epitope petide of 22-45 amino acid residues for inducing and/or enhancing an antigen-specific T-cell response |
FR2824326B1 (fr) | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
EP1479761A1 (de) | 2003-05-21 | 2004-11-24 | PrimaGen Holding B.V. | Neues Enterovirus, Vakzine, Medikamente und Diagnosekits |
CN104826116A (zh) * | 2003-11-20 | 2015-08-12 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
EP2138164A1 (de) * | 2005-06-17 | 2009-12-30 | Hospira Australia Pty Ltd | Flüssige pharmazeutische Docetaxel Zubereitungen |
ES2539812T3 (es) | 2007-03-26 | 2015-07-06 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos |
AU2008257791B2 (en) | 2007-05-31 | 2013-03-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | P53 peptide vaccine |
ES2482192T3 (es) * | 2007-05-31 | 2014-08-01 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Vacunación intradérmica del péptido de HPV |
CN101765607B (zh) | 2007-05-31 | 2015-09-09 | 莱顿教学医院 | 侵润宫颈恶性肿瘤的t细胞所靶向的用于疫苗的hpv表位 |
KR20090125629A (ko) | 2008-06-02 | 2009-12-07 | 바이오코아 주식회사 | 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물 |
KR20090125628A (ko) | 2008-06-02 | 2009-12-07 | 바이오코아 주식회사 | 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련질환 예방 또는 치료용 조성물 |
EP2429585B1 (de) * | 2009-05-15 | 2018-04-18 | IRX Therapeutics, Inc. | Impfstoff-immuntherapie |
CN105853348B (zh) * | 2011-03-10 | 2019-08-30 | Xeris药物公司 | 肠胃外注射用稳定溶液 |
WO2013006050A1 (en) | 2011-07-06 | 2013-01-10 | Isa Pharmaceuticals B.V. | Peptides inducing or enhancing an immune response against prostate-specific membrane protein (PSMA) |
NL2007536C2 (en) | 2011-10-05 | 2013-04-08 | Academisch Ziekenhuis Leiden Lumc | Adjuvant compound. |
WO2013113326A1 (en) * | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
US10501499B2 (en) * | 2012-06-06 | 2019-12-10 | Bionor Immuno As | Peptides derived from viral proteins for use as immunogens and dosage reactants |
GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
CA2950863C (en) | 2014-06-02 | 2023-01-17 | Isa Pharmaceuticals B.V. | Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection |
SG11201811442UA (en) * | 2016-06-20 | 2019-01-30 | Isa Pharmaceuticals B V | Formulation of a peptide vaccine |
-
2017
- 2017-06-19 SG SG11201811442UA patent/SG11201811442UA/en unknown
- 2017-06-19 CN CN201780051075.4A patent/CN109641039B/zh active Active
- 2017-06-19 KR KR1020237005809A patent/KR20230030032A/ko not_active Application Discontinuation
- 2017-06-19 CN CN202310680875.XA patent/CN117018170A/zh active Pending
- 2017-06-19 AU AU2017281389A patent/AU2017281389B2/en active Active
- 2017-06-19 WO PCT/EP2017/064882 patent/WO2017220463A1/en unknown
- 2017-06-19 KR KR1020197001793A patent/KR20190020098A/ko not_active IP Right Cessation
- 2017-06-19 EP EP17732070.2A patent/EP3471758A1/de active Pending
- 2017-06-19 EA EA201990071A patent/EA201990071A1/ru unknown
- 2017-06-19 MY MYPI2018002793A patent/MY189551A/en unknown
- 2017-06-19 JP JP2019518137A patent/JP7115803B2/ja active Active
- 2017-06-19 IL IL291537A patent/IL291537B2/en unknown
- 2017-06-19 CA CA3027459A patent/CA3027459A1/en active Pending
- 2017-06-19 EP EP19174463.0A patent/EP3552623A1/de active Pending
- 2017-06-19 MX MX2018015749A patent/MX2018015749A/es unknown
- 2017-06-19 US US16/311,629 patent/US10702598B2/en active Active
-
2018
- 2018-12-14 MX MX2023003875A patent/MX2023003875A/es unknown
- 2018-12-20 IL IL263846A patent/IL263846B/en unknown
-
2019
- 2019-01-18 ZA ZA2019/00367A patent/ZA201900367B/en unknown
-
2020
- 2020-06-10 US US16/898,141 patent/US11426458B2/en active Active
-
2021
- 2021-01-27 ZA ZA2021/00578A patent/ZA202100578B/en unknown
-
2022
- 2022-07-22 JP JP2022117117A patent/JP2022141878A/ja active Pending
- 2022-08-24 US US17/894,945 patent/US20230233658A1/en active Pending
-
2024
- 2024-03-05 JP JP2024033045A patent/JP2024069303A/ja active Pending
- 2024-03-28 AU AU2024202005A patent/AU2024202005A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2023003875A (es) | 2023-04-18 |
US10702598B2 (en) | 2020-07-07 |
ZA202100578B (en) | 2023-03-29 |
CA3027459A1 (en) | 2017-12-28 |
US20230233658A1 (en) | 2023-07-27 |
IL291537B2 (en) | 2023-11-01 |
AU2024202005A1 (en) | 2024-04-18 |
EP3552623A1 (de) | 2019-10-16 |
KR20230030032A (ko) | 2023-03-03 |
JP2022141878A (ja) | 2022-09-29 |
JP2024069303A (ja) | 2024-05-21 |
MY189551A (en) | 2022-02-16 |
IL291537B1 (en) | 2023-07-01 |
JP7115803B2 (ja) | 2022-08-09 |
US20190231863A1 (en) | 2019-08-01 |
US20200297835A1 (en) | 2020-09-24 |
CN109641039B (zh) | 2023-08-04 |
CN109641039A (zh) | 2019-04-16 |
JP2019525950A (ja) | 2019-09-12 |
US11426458B2 (en) | 2022-08-30 |
IL263846A (en) | 2019-01-31 |
AU2017281389A1 (en) | 2019-02-07 |
AU2017281389B2 (en) | 2024-02-22 |
EP3471758A1 (de) | 2019-04-24 |
IL291537A (en) | 2022-05-01 |
CN117018170A (zh) | 2023-11-10 |
WO2017220463A1 (en) | 2017-12-28 |
MX2018015749A (es) | 2019-06-17 |
ZA201900367B (en) | 2024-07-31 |
IL263846B (en) | 2022-04-01 |
EA201990071A1 (ru) | 2019-06-28 |
KR20190020098A (ko) | 2019-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
SG11201811338VA (en) | A novel botulinum neurotoxin and its derivatives | |
SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 |